Polyclonal Antibody to Alanine Glyoxylate Aminotransferase (AGXT)
| Code | Size | Price |
|---|
| PAC287Hu01-20ul | 20ul | £87.00 |
Quantity:
| PAC287Hu01-100ul | 100ul | £162.00 |
Quantity:
| PAC287Hu01-200ul | 200ul | £218.00 |
Quantity:
| PAC287Hu01-1ml | 1ml | £499.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Immunocytochemistry (ICC)
- Immunohistochemistry (IHC)
- Immunoprecipitation (IP)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
AGT; AGT1; AGXT1; PH1; SPAT; SPT; TLH6; Oxalosis I; Hyperoxaluria I; Glycolicaciduria; Serine-Pyruvate Aminotransferase
Buffer Formulation:
PBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
Item Name:
Alanine Glyoxylate Aminotransferase
Reactivity:
Mu;Ra;Po;
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 0.5-2ug/mL;1:440-1760
Immunohistochemistry: 5-20ug/mL;1:44-176
Immunocytochemistry: 5-20ug/mL;1:44-176
Optimal working dilutions must be determined by end user.
Immunohistochemistry: 5-20ug/mL;1:44-176
Immunocytochemistry: 5-20ug/mL;1:44-176
Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Alanine Glyoxylate Aminotransferase (AGXT) | RPC287Hu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||